Italian regulators find problems at Kores' API plant in Roha

By Gareth Macdonald contact

- Last updated on GMT


Related tags: European union

Italian regulators say Kores Limited’s facility in Roha, India should be banned from supplying the API ambroxol hydrochloride to the EU and advised users to find an alternative source.

The Italian Medicines Agency​ (AIFA) made the recommendation in a post on EudraGMDP​ today, explaining that inspectors who visited the site in April found evidence of breaches of serious GMP non-compliance.

The agency said: “Major deficiencies were found in the following areas: electronic and paper analytical data integrity, QC activities, computerised systems security, analytical and process data manipulation, personnel, deviations and OOS management leading to a serious risk for public health​.”

It suggested national competent authority (NCA) and drug firms that source the API from Kores “assess the opportunity of requesting variation to the marketing authorisation in order to delete or substitute this manufacturer of the active substance​.”

AFIA also said that drugs containing the ingredient should be recalled and retested, unless there are no alternative suppliers and there is a risk of shortage.

The agency also warned the deficiencies observed at the facility could affect APIs.

The site also makes doxofylline, etofylline, acefylline, glimepiride, 3-methylxanthine, 2-amino-3,5-dibromobenzaldehyde, 8-chlorotheophylline,8-benzyl theophylline, bromhexine HCl, acebrophylline, theophylline, piperazine/acepifylline, theobromine, orphenadrine citrate/ base, pamabrom, ivabradine HCl, dorzolamide Hydrochloride.

Related news

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more